Built for Indian
patients, not pharma.
GLP-1 Guide India was created because the information available to Indian patients about Ozempic, Wegovy, and Mounjaro is scattered, outdated, or written for Western audiences.
Indian patients face unique challenges: pricing in rupees, CDSCO approval status, cold-chain logistics in tier-2 cities, Indian dietary context for managing side effects, and access through doctors who may not be familiar with these newer medications.
We exist to fill that gap — with honest, evidence-based, India-specific information. We are not affiliated with any pharmaceutical company. We don't sell medications. We don't take advertising from drug makers.
Our Principles
Evidence-based only
Every claim we make is backed by peer-reviewed research or official regulatory data. We cite our sources. We update articles when evidence changes.
Independent & transparent
We have no pharmaceutical affiliations. No sponsored content. No paid reviews. If something doesn't work well for Indian patients, we'll say so.
Patient-first perspective
We write for patients, not doctors. We explain things in plain language, with an understanding of the real-world constraints Indian patients face — cost, access, diet, and lifestyle.
A note on medical advice
Nothing on this website constitutes medical advice. We are health journalists and researchers, not physicians. Always consult a qualified doctor — ideally an endocrinologist or obesity medicine specialist — before starting any GLP-1 medication.
GLP-1 medications are powerful drugs with real side effects and contraindications. They require proper medical supervision, monitoring, and titration. No website, no matter how well-intentioned, replaces a qualified physician.
Join the newsletter.
Monthly updates on GLP-1 access, pricing, and new research from India. No spam, ever.